Vivos Therapeutics Common Stock Net 2020-2025 | VVOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivos Therapeutics common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Vivos Therapeutics common stock net from 2020 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$67.7B
Zoetis (ZTS)	$65.3B
Daiichi Sankyo, - (DSNKY)	$46.2B
Takeda Pharmaceutical (TAK)	$45.9B
BeOne Medicines - (ONC)	$31.6B
Sandoz Group AG (SDZNY)	$25.8B
Summit Therapeutics (SMMT)	$21.3B
Merck (MKKGY)	$16.4B
Shionogi (SGIOY)	$15.2B
United Therapeutics (UTHR)	$13.6B
Neurocrine Biosciences (NBIX)	$12.4B
Orion OYJ (ORINY)	$10.8B
IPSEN (IPSEY)	$10.4B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.3B
Stevanato Group S.p.A (STVN)	$7.2B
Ionis Pharmaceuticals (IONS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.4B
Hypermarcas (HYPMY)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Crinetics Pharmaceuticals (CRNX)	$2.5B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B
Endo (NDOI)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.7B